Haemonetics Corporation (NYSE:HAE) Given Average Rating of “Moderate Buy” by Analysts

Shares of Haemonetics Corporation (NYSE:HAE) have been given an average rating of “Moderate Buy” by the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $78.8889.

A number of equities analysts recently issued reports on HAE shares. Mizuho increased their price objective on Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday. JPMorgan Chase & Co. cut their target price on Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $72.00 to $80.00 in a research note on Friday, May 22nd. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Finally, Robert W. Baird set a $67.00 price objective on shares of Haemonetics in a research note on Friday, May 8th.

Haemonetics Price Performance

NYSE HAE opened at $77.97 on Friday. Haemonetics has a 52 week low of $47.31 and a 52 week high of $87.32. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. The stock has a market cap of $3.54 billion, a price-to-earnings ratio of 38.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.52. The company has a 50-day moving average price of $70.49 and a two-hundred day moving average price of $66.25.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. The company had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. Haemonetics’s revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Analysts forecast that Haemonetics will post 5.21 EPS for the current year.

Institutional Trading of Haemonetics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its holdings in shares of Haemonetics by 372.8% in the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after acquiring an additional 1,678,630 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Haemonetics by 994.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock worth $110,615,000 after purchasing an additional 1,254,035 shares in the last quarter. Millennium Management LLC raised its holdings in Haemonetics by 4,296.3% during the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after purchasing an additional 755,592 shares in the last quarter. North Peak Capital Management LLC lifted its position in Haemonetics by 204.4% in the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after purchasing an additional 740,626 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in Haemonetics in the third quarter worth approximately $15,703,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.